Background: Lopinavir/Ritonavir (LPV/RTV) is widely used in HIV-infected children. In adults
LPV and RTV exposure has been associated with elevated total cholesterol (TCH) and …

Lopinavir (LPV)/ritonavir (RTV) used in combination, is a potent antiretroviral drug. However,
its benefit is limited by its inherent effect on lipid metabolism, causing dislypemia in a large …

We studied 382 multiexperienced HIV-infected patients followed up for≥ 3 months after
starting lopinavir/ritonavir (LPV/r) to identify the factors predicting hypertriglyceridemia and …

Background The relationship between lopinavir plasma concentration and the magnitude of
lipid elevation after initiation of lopinavir/ritonavir-containing antiretroviral therapy is unclear …

Objectives Ritonavir (RTV) at doses of 400 mg twice a day (bid) or higher adversely affects
serum lipids. However, the effect of RTV 100 mg bid on serum lipids is unknown. We …

Background Cardiovascular disease (CVD) is an emerging concern for HIV-infected
patients. Hyperlipidaemia is a risk factor for CVD and a complication of protease-inhibitor …

There does not appear to be any significant correlation between lopinavir/ritonavir
concentrations and lipid abnormalities, report researchers from Italy. To examine whether …

Objective: The aim of this study was to estimate the long-term metabolic effects of initiating a
lopinavir/ritonavir (LPV/r)-based regimen as a first-line therapy for HIV-infected children less …

Background Both HIV infection and antiretroviral therapy are associated with dyslipidemias
in adults, but there are fewer data on outcomes in young children. Here we examined lipid …

Objectives To study the impact of lopinavir/ritonavir-containing therapy on plasma lipids and
body fat of HIV-infected adults and to assess whether lopinavir plasma levels at steady state …